6111 Royalmount Avenue
Montreal, Quebec, CN H4P 2
www.pendopharm.com
Private
 Synopsis: Business Condition
Year Founded 1983
Employment 1,300
Sector N/A
Industry N/A
PendoPharma
     Last modified on: 7/8/2013

PENDOPHARM, Division of Pharmascience Inc. Established in 1983 and privately-owned, With a strong focus on specialty Mmedicines PENDOPHARM is a rapidly growing, independent business focused on commercializing a portfolio of specialty prescription products and an established line of OTC/BTC products. Strategically committed to growth, PENDOPHARM is actively engaged in licensing, developing and marketing late-stage prescription products as well as consumer brands. Partnership is a key component of the firm’s growth strategy with a business model focused on developing long-term alliances that create synergistic value for both parties by aligning the firm’s corporate capabilities, operations and resources to facilitate collaborations. The firm has the capability to provide expert regulatory filing, drug safety and medical information, logistics and distribution, customer service, manufacturing, sales/marketing, pricing, market access, and all other aspects of commercialization.

Pharmascience Inc. is the largest pharmaceutical company in Quebec, with a highly skilled workforce of 1,300 people. Pharmascience commercializes nearly 300 products in over 1,000 formats, including generic, branded prescription, OTC and BTC products. In Canada alone, more than 21 million prescriptions a year are filled with Pharmascience products. Additionally, Pharmascience has a significant international presence, with 25% of its sales coming from 60 countries. Operationally, Pharmascience is fully integrated and controls all aspects of production, from manufacturing to commercialization. It has state-of-the-art laboratory, manufacturing and research & development facilities, with the capability of manufacturing capsules, tablets, suppositories, liquids and suspensions. Financially, Pharmascience is well capitalized and has consistently experienced double-digit growth, with current sales of Cnd$700 million.